Status: Recruiting
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.
Participants needed: 420
Trial details
Phase: Phase 3Age: 18-60Biological sex: AllType: InterventionalSponsor: University of CologneUpdated: Jun 15, 2026Locations: 30
Eligibility criteria
Male and female patients with ADPKD (modified Ravine criteria) ≥ 18 and ≤ 60 yea... [+7]
Treatment with tolvaptan, somatostatin analogue, lithium or SGLT2i within the la... [+12]